WO2007007160A3 - Anti-madcam antibodies to treat fever - Google Patents

Anti-madcam antibodies to treat fever Download PDF

Info

Publication number
WO2007007160A3
WO2007007160A3 PCT/IB2006/001890 IB2006001890W WO2007007160A3 WO 2007007160 A3 WO2007007160 A3 WO 2007007160A3 IB 2006001890 W IB2006001890 W IB 2006001890W WO 2007007160 A3 WO2007007160 A3 WO 2007007160A3
Authority
WO
WIPO (PCT)
Prior art keywords
madcam antibodies
fever
treat fever
treatment
treat
Prior art date
Application number
PCT/IB2006/001890
Other languages
French (fr)
Other versions
WO2007007160A2 (en
Inventor
Gary Craig Burgess
Original Assignee
Pfizer Ltd
Gary Craig Burgess
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Gary Craig Burgess filed Critical Pfizer Ltd
Publication of WO2007007160A2 publication Critical patent/WO2007007160A2/en
Publication of WO2007007160A3 publication Critical patent/WO2007007160A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of fever in immunocompromised patients. Methods of treatment for fever in immunocompromised patients using a therapeutically effective amount of an anti-MAdCAM antibody are also included.
PCT/IB2006/001890 2005-07-11 2006-07-03 Anti-madcam antibodies to treat fever WO2007007160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69850505P 2005-07-11 2005-07-11
US60/698,505 2005-07-11

Publications (2)

Publication Number Publication Date
WO2007007160A2 WO2007007160A2 (en) 2007-01-18
WO2007007160A3 true WO2007007160A3 (en) 2007-05-18

Family

ID=37000142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001890 WO2007007160A2 (en) 2005-07-11 2006-07-03 Anti-madcam antibodies to treat fever

Country Status (1)

Country Link
WO (1) WO2007007160A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45847E1 (en) 2004-01-09 2016-01-19 Pfizer Inc. Antibodies to MAdCAM

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916283A1 (en) 2015-01-09 2016-07-09 Pfizer Inc. Dosage regimen for madcam antagonists
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
WO1998006248A2 (en) * 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
WO2005067620A2 (en) * 2004-01-09 2005-07-28 Pfizer Inc. ANTIBODIES TO MAdCAM

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
WO1998006248A2 (en) * 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
WO2005067620A2 (en) * 2004-01-09 2005-07-28 Pfizer Inc. ANTIBODIES TO MAdCAM

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GHOSH SUBRATA: "Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.", EXPERT OPINION ON BIOLOGICAL THERAPY. SEP 2003, vol. 3, no. 6, September 2003 (2003-09-01), pages 995 - 1000, XP009073000, ISSN: 1471-2598 *
LAZAR ALEXANDRU C ET AL: "Matrix-assisted laser desorption/ionization mass spectrometry for the evaluation of the C-terminal lysine distribution of a recombinant monoclonal antibody.", RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2004, vol. 18, no. 3, 2004, pages 239 - 244, XP009080137, ISSN: 0951-4198 *
LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364 - 370, XP004215163, ISSN: 0167-5699 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45847E1 (en) 2004-01-09 2016-01-19 Pfizer Inc. Antibodies to MAdCAM
US9328169B2 (en) 2004-01-09 2016-05-03 Pfizer Inc. Human antibodies that bind human MAdCAM

Also Published As

Publication number Publication date
WO2007007160A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
CY2017013I2 (en) ANTI-PDGFR-α ANTIBODY FOR USE IN THE THERAPEUTIC TREATMENT OF TUMORS
WO2010066803A3 (en) Human antibodies against human tissue factor
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
IL242434B (en) Antibody molecules having specificity for human il-6
PT1814915E (en) Neutralising antibodies having specificity for human il-17
MX2010006823A (en) Methods for the treatment of gout.
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
HK1151535A1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer -18
WO2009083009A3 (en) Monoclonal antibodies against cd32b
EP2103628A4 (en) Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
ZA200808865B (en) Antibody composition and methods for treatment of neoplastic disease
EP2023955A4 (en) Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
WO2005103081A3 (en) Human monoclonal antibodies against cd20
IL189788A0 (en) Human monoclonal antibodies to cd70
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
ZA200802641B (en) Human monoclonal antibodies to CD70
EP1789027A4 (en) Therapeutic use of anti-tf-antigen antibody
IL189004A0 (en) Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
EA201000433A1 (en) TREATMENT OF VASOMOTOR SYMPTOMS
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
WO2007007160A3 (en) Anti-madcam antibodies to treat fever
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
WO2007007159A3 (en) Anti-madcam antibodies to treat uterine disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06765627

Country of ref document: EP

Kind code of ref document: A2